Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)


levodopa / carbidopa / entacapone

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Corbilta. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Corbilta.

For practical information about using Corbilta, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 25/05/2020

Authorisation details

Product details
Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)
Agency product number
Active substance
  • levodopa
  • carbidopa
  • entacapone
International non-proprietary name (INN) or common name
levodopa / carbidopa / entacapone
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Orion Corporation
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Orionintie 1
02 200 Espoo

Product information

28/04/2020 Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz) - EMEA/H/C/002785 - N/0021


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Anti-Parkinson drugs

Therapeutic indication

Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.

Assessment history

How useful was this page?

Add your rating